Moleculin Net Working Capital from 2010 to 2024

MBRX Stock  USD 2.62  0.03  1.13%   
Moleculin Biotech Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2024. During the period from 2010 to 2024, Moleculin Biotech Net Working Capital regression line of annual values had r-squared of  0.36 and arithmetic mean of  15,452,300. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
19.5 M
Current Value
25.7 M
Quarterly Volatility
17.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Depreciation And Amortization of 120.7 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.02. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
  
Check out the analysis of Moleculin Biotech Correlation against competitors.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Latest Moleculin Biotech's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Moleculin Biotech over the last few years. It is Moleculin Biotech's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Moleculin Net Working Capital Regression Statistics

Arithmetic Mean15,452,300
Geometric Mean10,289,399
Coefficient Of Variation115.75
Mean Deviation12,398,840
Median6,087,000
Standard Deviation17,886,307
Sample Variance319.9T
Range64.8M
R-Value0.60
Mean Square Error220.4T
R-Squared0.36
Significance0.02
Slope2,401,030
Total Sum of Squares4478.9T

Moleculin Net Working Capital History

202425.7 M
202319.5 M
202240.8 M
202168.9 M
202014.3 M
20199.9 M
20184.1 M

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital19.5 M25.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.